Effects of Oligofructose and Barley on Satiety and Energy Intake
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00776256 |
Recruitment Status :
Completed
First Posted : October 21, 2008
Last Update Posted : October 21, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Appetite Regulation | Dietary Supplement: beta-glucan and fructooligosaccharide | Not Applicable |
Background: Increasing gastro-intestinal viscosity or colonic fermentation is suggested to help improve appetite control and reduce food intake. Beta-glucan (BG) and fructo-oligosaccharide (FOS) are food ingredients proposed to act this way, but results so far remain inconclusive.
Objective: To test the effect of FOS, BG, or their combination in bars on appetite ratings and food intake during 2 consecutive days.
Design: In a 4-way balanced order cross-over double-blind design, 21 healthy volunteers (mean BMI 25.9 kg/m2) received a meal replacement bar at 09.00h and an ad libitum lunch at 13.00h on 2 consecutive days. On day 1 only, subjects consumed a second (identical) bar at 17.00h and a fixed snack at 19.00h. The control bar contained 0.3g BG (control, from 6.8 g oats), vs equi-caloric bar formulations containing an additional: 1) 0.9 g BG (from 8.0g barley), 2) 8g FOS, or 3) 0.9 g BG + 8g FOS. Appetite scores and subsequent ad libitum test meal intakes were measured. Bar viscosities were determined under simulated gastric conditions. Results were analyzed using ANCOVA.
Results: Addition of BG, FOS or their combination did not affect appetite ratings or food intake, although addition of BG to the bar doubled apparent gastric viscosity (841 vs 351 mPa.s).
Conclusions: BG, FOS or their combination in bars at these levels do not improve appetite control when consumed on 2 consecutive days. Efficacy might be increased by a longer exposure period, increasing the BG content, or a form of BG that generates even higher gastric viscosity.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Official Title: | The Effect of Meal Replacement Bars Containing Different Types of Fibres (Oligofructose and/or Barley) on Satiety and Energy Intake |
Study Start Date : | February 2007 |
Actual Primary Completion Date : | March 2007 |
Actual Study Completion Date : | April 2007 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
effect of beta-glucan
|
Dietary Supplement: beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Other Names:
|
Active Comparator: 2
effect of fructo-oligosaccharide
|
Dietary Supplement: beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Other Names:
|
Active Comparator: 3
effect of beta-glucan and fructooligosaccharide
|
Dietary Supplement: beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Other Names:
|
Placebo Comparator: 4
no beta-glucan nor fructooligosaccharide
|
Dietary Supplement: beta-glucan and fructooligosaccharide
1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
Other Names:
|
- Satiety and food intake [ Time Frame: 2 days each week for 4 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age at start of the study 18 till 60 years
- Quetelet-Index (BMI) from 21 till 32 kg/m2 inclusive
- Apparently healthy: measured by questionnaire: no reported current or previous metabolic diseases or chronic gastrointestinal disorders
- Reported dietary habits: no medically prescribed diet, no slimming diet, used to eat 3 meals a day, no vegetarian, macro-biotic or biologic dynamic food habits
- No Fibre supplements (only once a day)
- No blood donations during the study.
- Reported intense sporting activities less than 10h/w
- Reported alcohol consumption less than 21 units/w (female volunteers) or less than 28 units/w (male volunteers)
- Having a General Practitioner
- Informed consent signed
- Recruitment form filled out
Exclusion Criteria:
- Smoking
- Dislike, allergy/intolerance or not known with the foods of the ad libitum meal
- Possible eating disorder (measured by SCOFF questionnaire)
- High or very high restrained eaters (measured by questionnaire) (men with BMI < 27: restraint score > 2.37, men with BMI less than 27: restraint score > 3.04, women with BMI < 26: restraint score > 3.24, women with BMI less than 26: restraint score > 3.41)
- Reported medical treatment that may affect eating habits/satiety
- Reported intolerance or allergy to test products
- Women reported lactating (or lactating < 6 weeks ago), pregnant (or pregnant < 3 months ago) or wish to become pregnant during the study
- Reported weight loss/gain (10%) in the last six month before the trial
- Reported participation in another biomedical trial 1 month before the start of the study
- Reported working on late turns -

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776256
Netherlands | |
Unilever R&D Vlaardingen | |
Vlaardingen, Netherlands, 3133AT |
Study Director: | Edward Haddeman | Unilever R&D |
Responsible Party: | Harry Peters, Unilever R&D |
ClinicalTrials.gov Identifier: | NCT00776256 |
Other Study ID Numbers: |
07002V |
First Posted: | October 21, 2008 Key Record Dates |
Last Update Posted: | October 21, 2008 |
Last Verified: | October 2008 |
satiety food intake |